Nidan Laborator. (NIDAN)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹14.95, Nidan Laborator is a tiny ₹22 crore healthcare services company. Let me be honest: in Graham's language, this is a speculation until I can dig deeper. The growth numbers catch my eye—sales up 24.6%, profit up 30%, and a PEG ratio of 0.35. At a P/E of 9.69, the market is not paying up for that growth. The Piotroski F-score of 7/9 also suggests reasonable financial health. But I cannot ignore what is missing. There is no disclosed book value, return on equity, or debt-to-equity ratio. In my world, if I cannot see the quality of the balance sheet and returns on tangible capital, I cannot call it a wonderful business. ROCE of 6.17% is modest—hardly a franchise with pricing power. Promoter holding of 57.04% is reassuring, but a ₹22 crore market cap means poor liquidity and higher risk. The stock trades near the lower end of its 52-week range, down from ₹24.90. There is no dividend, so any return depends entirely on share-price appreciation. Still, the latest quarter shows ₹13 crore sales and ₹1 crore net profit, meaning the business is real and profitable. If management can sustain 30% profit growth and improve returns on capital, the cheap P/E and PEG make it interesting. But I would need audited financials, cash-flow statements, and clarity on debt before putting a rupee in. For now, I see a small fast grower, but one that demands serious homework.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer